The article you requested is
Dr. Ketter and Colleagues Reply
J Clin Psychiatry 1997;58:362-363 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: We appreciate Dr. Feiner’s stimulating comments. We
wish to clarify that the patient in our report1 was taking benzodiazepines
(primarily alprazolam, but in some cases clonazepam)
to control anxiety during several of the antidepressant trials, and
in each case, tapering the benzodiazepine resulted in increased
anxiety and depression. Thus, the nefazodone plus alprazolam
combination was but one of several trials that combined antidepressants
with drugs (benzodiazepines) having anticonvulsant